Carl Zeiss Meditec Reports Strong Q2 Earnings for 2024/25

Carl Zeiss Meditec AG has posted a significant earnings increase in the second quarter of the fiscal year 2024/25. The company reported revenues of approximately EUR 560 million, marking a 19% increase compared to EUR 472.1 million in the previous year. This growth includes contributions from the acquisition of the Dutch Ophthalmic Research Center B.V. (DORC), which added EUR 54 million to the revenue. Excluding this, the revenue growth stands at 7%.

EBITA rose to about EUR 78 million from EUR 67.2 million, while earnings per share remained constant at EUR 0.52. The surge in revenue and earnings is attributed mainly to increased demand in China’s refractive surgery consumables market.

For the first half of 2024/25, the revenue amounted to EUR 1,050 million, with an EBITA of EUR 114 million. Despite macroeconomic challenges, Carl Zeiss Meditec anticipates moderate growth in revenue and stable to slightly increased EBITA for the fiscal year.